BRIDGEWATER, N.J., May 11, 2017 /PRNewswire/ -- Sanofi Consumer
Healthcare – the makers of Allegra® Allergy –
announced today that it is supporting Bike to Work Day events
across the country as a way to help reduce air pollution and to get
more people outdoors this spring. Allegra Allergy is an
antihistamine that helps relieve allergy symptoms that can hold
some people back from truly enjoying this season. Bike to Work Day
is an annual observance on which people are encouraged to ride
bicycles to work instead of driving, as a more environmentally
friendly form of transportation. It takes place on May 19th in most locations and on
June 28th in Denver, Colorado.
"Air pollution is one of the world's biggest global health
problems, so a lot of people feel like there isn't anything they
can do to make a difference but we want them to know that isn't the
case. Every step counts – or in this case, every bike ride,"
said Holly Sisson, Senior Marketing
Manager, Sanofi Consumer Healthcare. "That's why we are
supporting Bike to Work Day this year – it's a great way for people
to get involved, while also getting outside and enjoying the spring
season."
A recent survey found that a majority of Americans (88%) are
concerned about the impact of air pollution on their overall
health. It also found that most Americans (90%) wish there was more
they could do to get involved and help reduce air pollution.
Participating in Bike to Work Day is a great place to start.
A variety of Bike to Work Day events are available across the
country. Allegra will be supporting those taking place in
Philadelphia, PA, Dayton, OH, Chattanooga, TN, Denver, CO and the
Washington, D.C. metropolitan region. In certain locations, Allegra
will also be working with local bike share programs to offer free
24-hour bike passes in recognition of Bike to Work Day. For
additional information as these events near, follow Allegra on
Twitter and Facebook.
About Allegra® Allergy
Allegra® Allergy is an oral antihistamine that is
available over-the-counter at full prescription strength to relieve
indoor and outdoor allergy symptoms, including sneezing, runny
nose, itchy watery eyes, and itchy nose or throat. It provides
fast,** non-drowsy relief that starts in just one hour and stays
strong for 24.*** Allegra can be used by adults and children 12
years of age and older. For more information, visit
www.Allegra.com.
About Sanofi
Sanofi, a global healthcare
leader, discovers, develops and distributes therapeutic solutions
focused on patients' needs. Sanofi is organized into five global
business units: Diabetes and Cardiovascular, General Medicines and
Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer
Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
*This survey was conducted online using Toluna's QuickSurveys
methodology between January 22, 2017
and January 24, 2017 among 1,256
adults (ages 18 and over) in the USA. Respondents for Toluna
QuickSurveys are selected from among those who have agreed to
participate in Toluna surveys. Toluna's
SmartSelectTM methodology was used to promote sample
representativeness. SmartSelect relies on statistical matching
rather than probability sampling to select survey respondents,
based on demographic, attitudinal and behavioral characteristics
that match those of the target population. Figures for age, gender,
region, race/ethnicity, education and income are also weighted to
bring them into line with their actual proportions within the
population. Because the sample is based on those who agreed to
participate in Toluna surveys, no estimates of theoretical sampling
error can be calculated.
**Starts working in one hour. Use only as directed.
*** Applies to adult formulations only.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product
development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words "expects", "anticipates", "believes", "intends",
"estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
Sanofi's ability to benefit from external growth opportunities
and/or obtain regulatory clearances, risks associated with
intellectual property and any related pending or future litigation
and the ultimate outcome of such litigation, trends in
exchange rates and prevailing interest rates, volatile economic
conditions, the impact of cost containment initiatives and
subsequent changes thereto, the average number of shares
outstanding as well as those discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those
listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F
for the year ended December 31, 2016.
Other than as required by applicable law, Sanofi does not undertake
any obligation to update or revise any forward-looking information
or statements.
Contacts:
|
|
|
|
Media
Relations
Heather
Guzzi
Tel. : (908)
981-3164
heather.guzzi@sanofi.com
|
Media
Relations
Ashleigh
Koss
Tel. : (908)
981-8745
ashleigh.koss@sanofi.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allegra-allergy-gears-up-for-bike-to-work-day-across-the-us-300455665.html
SOURCE Sanofi